Skip to Main Content
Table 2—

Categories of risks in patients with type 1 or type 2 diabetes who fast during Ramadan

Very high risk 
    Severe hypoglycemia within the last 3 months prior to Ramadan 
    Patient with a history of recurrent hypoglycemia 
    Patients with hypoglycemia unawareness 
    Patients with sustained poor glycemic control 
    Ketoacidosis within the last 3 months prior to Ramadan 
    Type 1 diabetes 
    Acute illness 
    Hyperosmolar hyperglycemic coma within the previous 3 months 
    Patients who perform intense physical labor 
    Pregnancy 
    Patients on chronic dialysis 
High risk 
    Patients with moderate hyperglycemia (average blood glucose between 150 and 300 mg/dl, A1C 7.5–9.0%) 
    Patients with renal insufficiency 
    Patients with advanced macrovascular complications 
    People living alone that are treated with insulin or sulfonylureas 
    Patients living alone 
    Patients with comorbid conditions that present additional risk factors 
    Old age with ill health 
    Drugs that may affect mentation 
Moderate risk 
    Well-controlled patients treated with short-acting insulin secretagogues such as repaglinide or nateglinide 
Low risk 
    Well-controlled patients treated with diet alone, metformin, or a thiazolidinedione who are otherwise healthy 
Very high risk 
    Severe hypoglycemia within the last 3 months prior to Ramadan 
    Patient with a history of recurrent hypoglycemia 
    Patients with hypoglycemia unawareness 
    Patients with sustained poor glycemic control 
    Ketoacidosis within the last 3 months prior to Ramadan 
    Type 1 diabetes 
    Acute illness 
    Hyperosmolar hyperglycemic coma within the previous 3 months 
    Patients who perform intense physical labor 
    Pregnancy 
    Patients on chronic dialysis 
High risk 
    Patients with moderate hyperglycemia (average blood glucose between 150 and 300 mg/dl, A1C 7.5–9.0%) 
    Patients with renal insufficiency 
    Patients with advanced macrovascular complications 
    People living alone that are treated with insulin or sulfonylureas 
    Patients living alone 
    Patients with comorbid conditions that present additional risk factors 
    Old age with ill health 
    Drugs that may affect mentation 
Moderate risk 
    Well-controlled patients treated with short-acting insulin secretagogues such as repaglinide or nateglinide 
Low risk 
    Well-controlled patients treated with diet alone, metformin, or a thiazolidinedione who are otherwise healthy 
Close Modal

or Create an Account

Close Modal
Close Modal